Protocol Ledger

NCT06072612 · Phase III · RECRUITING

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Interventional Phase III clinical trial protocol NCT06072612 sponsored by BriaCell Therapeutics in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-12-05 Enrollment: 404 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06072612
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)404 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06072612
Protocol FieldVerified Registry Value
NCT IdentifierNCT06072612
Consolidated Lead SponsorBriaCell Therapeutics
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment404 participants (ESTIMATED)
Registered Start Date2023-12-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06072612
Hospital Research SiteLocationSite Profile
Mayo Clinic ArizonaPhoenix, AZOpen Hospital Dossier ->
Cedars-Sinai Medical CenterLos Angeles, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI